Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed) | RFA HG 22 010

Opportunity Information: Apply for RFA HG 22 010

The NIH funding opportunity RFA-HG-22-010, titled "Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)," supports the creation of a single Data Analysis and Coordination Center (DACC) to serve as the organizing and analytic hub for a larger multi-site consortium. The broader initiative is designed to push multi-omics approaches (the combined use of multiple molecular data types, such as genomics, transcriptomics, proteomics, metabolomics, and related assays) into real-world studies of health and disease in diverse populations. Rather than being a stand-alone research project, the DACC is intended to operate as a cooperative partner with NIH and with other funded components of the consortium, especially the Disease Study Sites (RFA-HG-22-008) and the Omics Production Center(s) (RFA-HG-22-009).

At a high level, the consortium is built around clinical conditions where multi-omics is expected to be especially informative. The DACC helps the consortium accomplish three main goals: first, to evaluate how multi-omic data, when integrated with phenotypic information and environmental exposure data (including social determinants of health, or SDOH), can detect and characterize molecular profiles associated with both healthy and disease states; second, to develop methods that are broadly usable beyond this specific program, including approaches for data harmonization, integration, analysis, and the establishment of best practices and standards for applying multi-omics well; and third, to produce a high-value, multi-dimensional dataset that can be shared with and used by the wider research community. A key theme running through the FOA is generalizability: the emphasis is less on proving one specific disease mechanism and more on validating and improving multi-omic strategies that can be reused across diseases, populations, and settings.

The DACC is described as the primary center for consortium coordination and operations. That includes managing logistics across participating sites, supporting communication and collaboration, organizing outreach activities, and helping disseminate findings. It also includes core data responsibilities: managing, securing, and coordinating consortium data flows so that the resulting integrated dataset is consistent, well documented, and suitable for broader sharing. In practical terms, this kind of center typically sets up common data models, establishes data submission and quality control pipelines, tracks metadata and provenance, and ensures that data from multiple sources (clinical measures, omics outputs, exposure variables, and SDOH-related variables) can be linked and analyzed together in a reliable way.

Beyond data stewardship, the DACC is expected to actively contribute to consortium-wide scientific work in protocol development and methods development. That means helping create or refine common protocols that allow data to be comparable across sites, and developing analytic strategies that can handle the complexity of multi-omic integration. The DACC is positioned to lead or coordinate cross-consortium analyses, support reproducible workflows, and help define standards and best practices that other researchers can adopt. Although the program may yield insights into disease etiology as a byproduct, the FOA makes it clear that the central objective is methodological and infrastructural: improving how multi-omic approaches are executed, integrated with contextual data, and translated into meaningful biological signals related to health and disease.

This opportunity uses the NIH U01 mechanism, which is a cooperative agreement. That indicates substantial NIH involvement during the project period, with NIH program staff participating in steering and coordination activities rather than acting only as a funder. The FOA is labeled "Clinical Trial Not Allowed," meaning applicants should not propose work that meets NIH's definition of a clinical trial (for example, prospective assignment of human participants to interventions to evaluate effects on health-related outcomes). The work is focused on data coordination, analysis, and methods development within observational or non-interventional frameworks consistent with the FOA.

In terms of who can apply, eligibility is broad across U.S.-based organizations, including state, local, and tribal governments; public and private institutions of higher education; nonprofits (with or without 501(c)(3) status); for-profit organizations other than small businesses; and small businesses, among others. The FOA explicitly highlights additional eligible applicant types such as HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs, as well as faith-based or community-based organizations and regional organizations. Foreign institutions (non-U.S. entities) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply; however, foreign components are allowed as defined by the NIH Grants Policy Statement, which typically means certain discrete project elements may be carried out abroad when well justified and compliant with NIH policy.

Administrative details included in the source information indicate the sponsoring agency is the National Institutes of Health and the funding instrument type is a cooperative agreement. The opportunity lists an award ceiling of $950,000. The original closing date shown is 2022-11-18, and the opportunity was created on 2022-09-07. The CFDA (assistance listing) numbers provided are 93.113, 93.172, 93.396, and 93.399, reflecting the NIH program areas associated with this initiative.

• The National Institutes of Health in the education, environment, health sector is offering a public funding opportunity titled "Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.172, 93.396, 93.399.
• This funding opportunity was created on 2022-09-07.
• Applicants must submit their applications by 2022-11-18. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $950,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HG 22 010

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: